Screener
Travere Therapeutics, Inc. TVTX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 / Shares | Three Months Ended March 31, 2026 / Net Loss | Three Months Ended March 31, 2026 / EPS | Three Months Ended March 31, 2025 / Shares | Three Months Ended March 31, 2025 / Net Loss | Three Months Ended March 31, 2025 / EPS |
|---|---|---|---|---|---|---|
| Continuing operations | 91,868,862 | $(36,602) | $(0.40) | 88,355,973 | $(41,226) | $(0.47) |
| Discontinued operations | 91,868,862 | (500) | — | 88,355,973 | — | — |
| Basic and diluted loss per share | 91,868,862 | $(37,102) | $(0.40) | 88,355,973 | $(41,226) | $(0.47) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s shares (diluted)?
- Travere Therapeutics, Inc. (TVTX) reported shares (diluted) of 91.9M in Q1 2026.
- How has Travere Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Travere Therapeutics, Inc.'s shares (diluted) increased by 4.0% year-over-year, from 88.4M to 91.9M.
- What is the long-term trend for Travere Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s shares (diluted) has grown at a 11.7% compound annual growth rate (CAGR), from 237.5M to 369.1M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Travere Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude